Objective: To better understand Aeromonas-involved polymicrobial bacteremia (AIPMB).
Introduction
The proportion of cases of bacteremia involving more than one species has ranged from 5% to 20% over the past 50 years [1] . Polymicrobial bacteremia is associated with malignancy, surgery and the placement of central venous catheters [1] . The mortality in patients with polymicrobial bacteremia is approximately twice that of patients with monomicrobial bacteremia [2e4] .
Aeromonas, a member of the Aeromonadaceae family, is associated with a variety of human infections including gastroenteritis, wound infection and septicemia [5e8] . Aeromonas infection is mainly acquired from the environment, especially contaminated water. In previous studies, there have been high proportions of polymicrobial infection where Aeromonas spp. have been involved in infections of the bloodstream [9e14] . No study has yet delineated the clinical picture of Aeromonas-involved polymicrobial bacteremia (AIPMB), possibly because of a lack of sufficient cases in a single healthcare institution. We therefore conducted a retrospective multicenter study of AIPMB.
Materials and methods
This is a retrospective study of patients diagnosed with AIPMB admitted to Buddhist Tzu Chi General, Buddhist Dalin Tzu Chi General and Buddhist Taipei Tzu Chi General Hospitals in Taiwan between January 2001 and November 2008. Patient data, clinical and laboratory information were retrieved from the medical charts of the patients included in the study.
An AIPMB was defined as the simultaneous growth of an Aeromonas spp. and at least one other microbe from the blood culture of a patient with sepsis. Death was considered attributable to AIPMB if the patient died of unrelenting sepsis within 7 days after blood was sampled for culture where the culture was positive for Aeromonas species and one or more other microbes.
An AIPMB was considered healthcare-associated if the Aeromonas isolate was obtained from blood sampled 72 hours after admission to the hospital in a patient who had been asymptomatic upon admission, or in a patient who had received antineoplastic chemotherapy within the past 2 weeks, regardless of his or her symptoms at admission [15] . Acute respiratory failure was defined as the ratio of arterial oxygen tension (PaO 2 ) to fractional inspired oxygen (FiO 2 ) <200 [16] . The severity of the AIPMB was assessed using the Acute Physiology and Chronic Health Evaluation II (APACHE II) score less than 72 hours after the development of sepsis [17] .
Gastric acid-suppressant therapy was defined as the use of a proton-pump inhibitor or a histamine H 2 blocker for 7 days within 4 weeks before the emergence of an AIPMB.
Species identification and antimicrobial susceptibility
Detection of bacterial growth from blood specimens was performed using the BACTEC 9240 blood culture system (BD Diagnostic Instrument Systems, Spark, MD, USA). Aeromonas species (Gram-negative bacilli) were identified by a positive oxidase test, growth on MacConkey agar, no growth on thiosulfate-citrate-bilesucrose agar, and resistance to 150 mg vibriostatic compound O/ 129 [5, 18] . Isolates were further confirmed with use of the Vitek II system (BioMérieux, Lyon, France), BD-Phoenix system (BD Diagnostic Instrument Systems, Spark, MD, USA) or API-20NE system (BioMérieux Marcy-I'Etoile, France). Additional tests, such as esculin hydrolysis, gas production from glucose, Voges-Proskauer reaction, ornithine decarboxylase and arginine dihydrolase production, were performed for the identification of bacterial species as necessary [5, 18] .
In vitro antimicrobial susceptibilities of Aeromonas isolates were tested using the Kirby-Bauer disk-diffusion method or automated methods (Vitek II system or the BD-Phoenix system). All of the methods tested for gentamicin, amikacin, cefazolin, ceftriaxone, ciprofloxacin, piperacillin/tazobactam and imipenem. The BDPhoenix system also ran tests including aztreonem. In the diskdiffusion method, antibiotics selected for testing also included cefmetazole, cefuroxime, ceftazidime, cefpirome and aztreonam. There were, however, some differences in the antibiotics selected for different Aeromonas isolates tested using the disk-diffusion method. The susceptibility breakpoints in the disk diffusion method were in accordance with those of the National Committee for Clinical Laboratory Standards for Enterobacteriaceae [19] , while the susceptibility breakpoints in the automated methods were in accordance with those recommended by the Clinical and Laboratory Standards Institute M45-A [20] .
Statistical analyses
The Chi-square test or Fisher's exact test was used to compare nominal data using the SPSS software package, version 11.0 (SPSS Inc, Chicago, IL, USA). A two-tailed p value of 0.05 was considered statistically significant.
Results
Of a total of 62 patients [mean age 62 years (range: 24e90 years); males: 33/62] with AIPMB, 22 had healthcare-associated infection and 40 had community-acquired infection. Four patients presented with necrotizing fasciitis, one with acute cholangitis and the others with primary bacteremia. Fifty-one patients (82%) had Enterobacteriaceae coinfection. Solid cancer (45%) was the most common underlying disease/condition, followed by gastric acid suppressant therapy (39%) and liver cirrhosis (26%). Forty-five patients (73%) presented with fever, 31 (50%) with thrombocytopenia and only 23 (37%) with leukocytosis. Eighteen (29%) patients had very severe disease (APACHE II score 20) and the overall mortality rate of AIPMB was 31% (19/62). The clinical characteristics of healthcare-associated and community-acquired AIPMBs are detailed in Table 1 . The ratios of male gender and Enterobacteriaceae coinfection were significantly higher in community-acquired AIPMB than in healthcare-associated APIMB.
The concurrent pathogens for healthcare-associated and community-acquired AIPMBs are listed in Table 2 . In communityacquired infection, Escherichia coli (23/40, 58%) was most commonly found, followed by Klebsiella spp. (9/40, 23%) and Enterobacter spp. (5/40, 13%) . In healthcare-associated infection, Klebsiella spp. (5/22, 23%) were most frequently found, followed by Enterobacter spp. (5/22, 23%) and Acinetobacter spp. (5/22, 23%) .
The in vitro antimicrobial susceptibilities of Aeromonas isolates are listed in Table 3 . There were 44 Aeromonas isolates tested by the disk-diffusion method, 12 by the Vitek II system and six by the BDPhoenix system. The majority of Aeromonas isolates were susceptible to amikacin, gentamicin, ceftriaxone, ceftazidime, cefpirome, aztreonam, piperacillin/tazobactam, imipenem and ciprofloxacin. Thirty-nine out of 49 (80%) isolates tested were susceptible to cefuroxime, 15 of 62 (24%) were susceptible to cefazolin, and 23 of 41 (56%) were susceptible to cefmetazole. Antibiotic susceptibilities were not statistically different between community-acquired and healthcare-associated Aeromonas isolates.
Discussion
In agreement with previous reports [9e14], the majority of AIPMBs were of primary bacteremia. Aeromonas spp. exist in the environment, especially in fresh water. They are not considered as commensal organisms in the human gastrointestinal tract but can be isolated from feces in asymptomatic people [21] . Of all Aeromonas species, A hydrophila, A sobria and A caviae are the most common in human infection. In a mouse model, these three Aeromonas species were found to have higher colonization rates in colon tissue compared with other Aeromonas species [22] . Low-pH stomach acid has been reported to be effective in killing Aeromonas [23] . The high proportion of patients with AIPMB with prior gastric acid-suppressant therapy in this study therefore suggests that a higher pH milieu in the stomach enhances chances of Aeromonas intestinal colonization. The findings that Enterobacteriaceae are the most common concurrent pathogens for AIPMB in other reports and ours further support the gastrointestinal tract as the most likely portal of entry for Aeromonas leading to bacteremia [12e14] .
Of all bacteremia cases, a higher proportion of polymicrobial bacteremia is reported in cancer patients compared with their noncancer counterparts [24, 25] . Of note, one study found polymicrobial bloodstream infection in 14% of 2340 patients with an underlying malignancy and an episode of nosocomial bloodstream infection [1] . Neutropenia and disruption of the digestive mucosal barrier caused by antineoplastic therapy, surgery or hypoxia in cancer patients enables the invasion of various bacteria, especially from the gut and oropharynx [1, 26] . In agreement with these findings, 12 of the 28 cancer patients in the present study had abdominal surgery, eight had received antineoplastic therapy, two had received radiotherapy and six had septicemia shortly before AIPMB occurred.
Cirrhosis plays an important role in the pathogenesis of AIPMB as it leads to many alterations in the immune system, including decreased reticuloendothelial phagocytic activity, deficient ascetic fluid opsonic activity and qualitative neutrophil dysfunction [27e30]. Cirrhosis-associated portal hypertension could alter intestinal permeability as a result of intestinal congestion, edema and local hypoxia [31e36] .
In this study, >85% of Aeromonas isolates in both communityacquired and healthcare-associated AIPMB were susceptible to gentamicin, amikacin, ceftriaxone, ceftazidime, cefpirome, aztreonam, piperacillin/tazobactam, imipenem and ciprofloxacin. The similarity in antibiotic susceptibility suggests that the bloodstreaminvasive Aeromonas in healthcare-associated infections existed in the gastrointestinal tracts of affected patients before hospitalization and were not acquired from the institutional environment [8] . The difference in concurrent pathogens in AIPMB between healthcareassociated and community-acquired patients might result from the alteration of microbes that inhabit the patients' bowel after hospitalization [37] and which then invade the bloodstream leading to the development of bacteremia. Non-Enterobacteriaceae from hospital environments, such as non-fermentative Gram-negative bacilli or Gram-positive bacteria, can colonize patients' gastrointestinal tracts while they are hospitalized.
One limitation of this study was that the Aeromonas isolates could not be identified to species level, as neither automated system (i.e., the API-20NE, Vitek II system and BD-Phoenix system) nor conventional biochemical reactions were ideal for this task.
Conclusions
The most common underlying diseases/conditions in patients with AIPMB were solid tumors, liver cirrhosis and gastric acid suppressant therapy. Although Enterobacteriaceae were the most common concurrent pathogens for AIPMB, no significant difference in antibiotic susceptibility was found between Aeromonas isolates in healthcare-associated and community-acquired AIPMBs. Table 3 In vitro antibiotic susceptibilities of the Aeromonas isolates.
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